Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Roy Buchanan - Citizens Jonathan Miller - Evercore ISI Phil Nadeau - TD Cowen Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago.
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
Goldman Sachs downgraded Dynavax Technologies Corporation DVAX reflecting updated views and recent competitive dynamics for vaccines.
Wall Street Analysts Believe Dynavax Technologies (DVAX) Could Rally 93.2%: Here's is How to Trade
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 93.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies (DVAX) Upgraded to Buy: Here's What You Should Know
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Dynavax Technologies: What The Stock Buyback Means. What It Doesn't
Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B continues to increase market share consistently in a growing market. The company has also moved towards profitability and analyst firms have price targets significantly above the current trading level of the stock, even after its recent rally.
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know
The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Dynavax Technologies (DVAX) Q3 Earnings Surpass Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.
